Circulating tumor markers in breast cancer: Accepted utilities and novel prospects

Vered Stearns, Hideko Yamauchi, Daniel F. Hayes

Research output: Contribution to journalArticle

Abstract

Detecting and/or monitoring changes in circulating tumor markers might assist in evaluating cancer risk, diagnosis, prognosis, or response to treatment. Several categories of circulating tumor markers have been investigated in breast cancer. These categories include classical tumor-associated antigens, such as CEA and CA 15-3, markers of tumor biology, including markers of angiogenesis, adhesion, and invasion, and antibody response to tumor-associated antigens such as HER2/neu and p53. We used a recently proposed Tumor Marker Utility Grading System to evaluate the use of several circulating tumor markers for different clinical utilities in breast cancer. While there are no tumor markers with established clinical utilities for most uses, tumor-associated antigens can be used for monitoring patients with metastatic disease. In addition, markers of tumor biology such as the circulating extracellular domain of HER2/neu might be useful in determining not only prognosis, but also response to specific treatments. However, further investigations are required to further assess the utility of individual tumor markers for specific clinical uses.

Original languageEnglish (US)
Pages (from-to)239-259
Number of pages21
JournalBreast Cancer Research and Treatment
Volume52
Issue number1-3
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Tumor Biomarkers
Breast Neoplasms
Neoplasm Antigens
Physiologic Monitoring
Antibody Formation
Neoplasms

Keywords

  • Breast cancer
  • Metastatic disease
  • Serum markers
  • Tumor markers
  • Tumor-associated antigens

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Circulating tumor markers in breast cancer : Accepted utilities and novel prospects. / Stearns, Vered; Yamauchi, Hideko; Hayes, Daniel F.

In: Breast Cancer Research and Treatment, Vol. 52, No. 1-3, 1998, p. 239-259.

Research output: Contribution to journalArticle

@article{c3e1dfb13c1b4e9fab58056f50364452,
title = "Circulating tumor markers in breast cancer: Accepted utilities and novel prospects",
abstract = "Detecting and/or monitoring changes in circulating tumor markers might assist in evaluating cancer risk, diagnosis, prognosis, or response to treatment. Several categories of circulating tumor markers have been investigated in breast cancer. These categories include classical tumor-associated antigens, such as CEA and CA 15-3, markers of tumor biology, including markers of angiogenesis, adhesion, and invasion, and antibody response to tumor-associated antigens such as HER2/neu and p53. We used a recently proposed Tumor Marker Utility Grading System to evaluate the use of several circulating tumor markers for different clinical utilities in breast cancer. While there are no tumor markers with established clinical utilities for most uses, tumor-associated antigens can be used for monitoring patients with metastatic disease. In addition, markers of tumor biology such as the circulating extracellular domain of HER2/neu might be useful in determining not only prognosis, but also response to specific treatments. However, further investigations are required to further assess the utility of individual tumor markers for specific clinical uses.",
keywords = "Breast cancer, Metastatic disease, Serum markers, Tumor markers, Tumor-associated antigens",
author = "Vered Stearns and Hideko Yamauchi and Hayes, {Daniel F.}",
year = "1998",
doi = "10.1023/A:1006137619153",
language = "English (US)",
volume = "52",
pages = "239--259",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1-3",

}

TY - JOUR

T1 - Circulating tumor markers in breast cancer

T2 - Accepted utilities and novel prospects

AU - Stearns, Vered

AU - Yamauchi, Hideko

AU - Hayes, Daniel F.

PY - 1998

Y1 - 1998

N2 - Detecting and/or monitoring changes in circulating tumor markers might assist in evaluating cancer risk, diagnosis, prognosis, or response to treatment. Several categories of circulating tumor markers have been investigated in breast cancer. These categories include classical tumor-associated antigens, such as CEA and CA 15-3, markers of tumor biology, including markers of angiogenesis, adhesion, and invasion, and antibody response to tumor-associated antigens such as HER2/neu and p53. We used a recently proposed Tumor Marker Utility Grading System to evaluate the use of several circulating tumor markers for different clinical utilities in breast cancer. While there are no tumor markers with established clinical utilities for most uses, tumor-associated antigens can be used for monitoring patients with metastatic disease. In addition, markers of tumor biology such as the circulating extracellular domain of HER2/neu might be useful in determining not only prognosis, but also response to specific treatments. However, further investigations are required to further assess the utility of individual tumor markers for specific clinical uses.

AB - Detecting and/or monitoring changes in circulating tumor markers might assist in evaluating cancer risk, diagnosis, prognosis, or response to treatment. Several categories of circulating tumor markers have been investigated in breast cancer. These categories include classical tumor-associated antigens, such as CEA and CA 15-3, markers of tumor biology, including markers of angiogenesis, adhesion, and invasion, and antibody response to tumor-associated antigens such as HER2/neu and p53. We used a recently proposed Tumor Marker Utility Grading System to evaluate the use of several circulating tumor markers for different clinical utilities in breast cancer. While there are no tumor markers with established clinical utilities for most uses, tumor-associated antigens can be used for monitoring patients with metastatic disease. In addition, markers of tumor biology such as the circulating extracellular domain of HER2/neu might be useful in determining not only prognosis, but also response to specific treatments. However, further investigations are required to further assess the utility of individual tumor markers for specific clinical uses.

KW - Breast cancer

KW - Metastatic disease

KW - Serum markers

KW - Tumor markers

KW - Tumor-associated antigens

UR - http://www.scopus.com/inward/record.url?scp=0032431294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032431294&partnerID=8YFLogxK

U2 - 10.1023/A:1006137619153

DO - 10.1023/A:1006137619153

M3 - Article

C2 - 10066086

AN - SCOPUS:0032431294

VL - 52

SP - 239

EP - 259

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1-3

ER -